Spectrum Pharmaceuticals, Inc. Announces Record Revenue Growth in Fourth Quarter and Fiscal Year 2010; Ends Year with $104 Million in Cash, Cash Equivalents and Investments

IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced preliminary unaudited fourth quarter and fiscal 2010 revenues.